SCA
RARE icon

Spearhead Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Spearhead Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,232
Closed -$252K – 148
2022
Q2 		$252K Sell
4,232
-58
-1% -$3.57K 0.04% 140
2022
Q1 		$312K Buy
4,290
+381
+10% +$26.5K 0.04% 129
2021
Q4 		$329K Buy
3,909
+388
+11% +$31.6K 0.04% 140
2021
Q3 		$318K Buy
3,521
+203
+6% +$18.3K 0.04% 146
2021
Q2 		$316K Buy
3,318
+550
+20% +$57.3K 0.04% 174
2021
Q1 		$315K Buy
+2,768
New +$377K 0.05% 157

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Spearhead Capital Advisors's RARE Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 4,232 shares — an estimated $252K sold.

Spearhead Capital Advisors first reported a position in RARE in Q1 2021 and held it in 6 quarters. The position peaked at $329K in Q4 2021. 233 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 4,232 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $252K.
  • Spearhead Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 6 quarters.
  • Spearhead Capital Advisors's Ultragenyx Pharmaceutical position peaked at $329K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.